The healthcare industry, often referred to as 'Big Medicine,' has become a formidable force, impacting both our wallets and our well-being. However, amidst this complex landscape, there's a glimmer of hope for reform. In this article, I'll delve into the intricacies of this issue, offering my insights and analysis along the way.
The Middlemen's Dilemma
Pharmacy Benefit Managers (PBMs) are the unsung middlemen in the healthcare ecosystem. Their role, ostensibly to reduce drug costs, has instead led to inflated prices and a skewed market. The New York Times exposed this in 2024, revealing how PBMs steer patients towards pricier medications and extract hidden fees, contributing to the high cost of healthcare in the U.S.
Unraveling the Web of Influence
The 'Big Three' PBMs - CVS Caremark, Cigna's Express Scripts, and UnitedHealth Group's Optum Rx - control a staggering 80% of U.S. prescriptions. But their influence doesn't stop there. These companies are vertically integrated with major insurance conglomerates and pharmacies, creating a monopoly-like grip on the market. The Federal Trade Commission's report in 2025 highlighted this, showing how these PBMs paid their affiliated pharmacies up to 7,736% more than unaffiliated competitors, effectively driving independent pharmacies out of business.
The Wholesalers' Role
Drug wholesalers like McKesson, Cencora, and Cardinal Health control 96% of U.S. drug distribution. Their increasing vertical integration with medical providers, especially in high-cost specialty practices, raises ethical concerns. For instance, Cencora's $1 million settlement over allegations of paying kickbacks to healthcare providers to influence drug choices is a red flag. This practice undermines the very essence of medical decision-making, putting profit before patient welfare.
The Battle for Reform
PBMs have been quick to shift blame, launching expensive ad campaigns to point fingers at the pharmaceutical industry. While Big Pharma's patent abuses are well-documented, it doesn't absolve Big Medicine of its responsibilities. The industry's fierce opposition to reform efforts is a testament to its power and influence. Even Elon Musk, unknowingly, played a part in derailing PBM reforms, highlighting the industry's reach.
A Step Towards Change
Lawmakers have made some progress. The recent spending bill included provisions to ban PBMs from pocketing manufacturer rebates and to ensure independent pharmacies are not excluded from networks. However, these reforms don't address the root cause - the vertically integrated business model of the 'Big Three' PBMs.
Breaking Up is Hard to Do
The Break Up Big Medicine Act, introduced by Senators Elizabeth Warren and Josh Hawley, aims to do just that - break up the six major Big Medicine companies. This act would prohibit insurers, PBMs, and wholesalers from owning or controlling healthcare providers, promoting competition and potentially lowering healthcare costs. Research supports this, showing that UnitedHealthcare pays its affiliated Optum providers significantly more than competitors, especially in markets where UnitedHealthcare has a substantial market share.
A Growing Movement
Public support for such reforms is gaining momentum. A recent poll found that a vast majority of voters believe health insurance companies have too much control and drive up costs. Business leaders like Mark Cuban endorse this break-up, and organizations like the American Economic Liberties Project, where I work, are part of a coalition advocating for this change. The parallels with the Glass-Steagall Act, which separated commercial and investment banks during the Great Depression, are striking. Big Medicine poses a similar threat to the healthcare system, and the Break Up Big Medicine Act could be a crucial step towards recovery.
In my opinion, this act is a necessary disruption to a broken system. It challenges the status quo and offers a chance to reshape the healthcare landscape, putting patients and providers first. While it won't solve all the system's problems, it's a bold move towards a more equitable and affordable healthcare future.
